Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Subjects with moderate to severe plaque psoriasis on etanercept treatment according to the Summary of Product Characteristics (SmPC), and applicable local guidelines

• Subjects for whom the decision has already been made to initiate treatment with etanercept

Exclusion Criteria:

• Sepsis or risk of sepsis

• Current or recent infections, including chronic or localized, e.g. tuberculosis (TB) infection

• Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study

• Pre-existing or recent onset CNS demyelinating disease.

• Class III or IV congestive heart failure as defined by the New York Heart Association classification or uncompensated congestive heart failure.

• Previous or ongoing treatment with etanercept

• Participation in other clinical or observational studies.

• Patients with psoriatic arthritis requiring continuous etanercept treatment.